CDKN2A and lung carcinoma: The TP53 (c.532C > G, exon 5, H178D; LOH) mutation [previously found in breast, genital tract, ovary, endometrial and lung cancers (COSMIC)] and homozygous CDKN2A loss that we identified in 2XSB cells promote genomic instability and loss of cell cycle checkpoints in other cancer types.